June 17 (Reuters) - Eli Lilly ( LLY ) will acquire Verve
Therapeutics ( VERV ) for up to $1.3 billion, the companies said
on Tuesday.
Verve is developing therapies targeting genes that regulate
cholesterol in the liver.